Idorsia Ltd (IDRSF)
IDRSF Stock Price Chart
Explore Idorsia Ltd interactive price chart. Choose custom timeframes to analyze IDRSF price movements and trends.
IDRSF Company Profile
Discover essential business fundamentals and corporate details for Idorsia Ltd (IDRSF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Jul 2017
Employees
1.10K
Website
https://www.idorsia.comCEO
Andre C. Muller
Description
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
IDRSF Financial Timeline
Browse a chronological timeline of Idorsia Ltd corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 28 Apr 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 30 Oct 2025
Earnings released on 30 Jul 2025
EPS came in at -$0.08 surpassing the estimated -$0.25 by +69.84%, while revenue for the quarter reached $90.92M , beating expectations by +118.59%.
Earnings released on 30 Apr 2025
EPS came in at $0.39 surpassing the estimated -$0.29 by +234.01%, while revenue for the quarter reached $69.14M , beating expectations by +37.65%.
Earnings released on 4 Mar 2025
EPS came in at -$0.49 surpassing the estimated -$0.62 by +20.33%, while revenue for the quarter reached $65.95M , beating expectations by +232.78%.
Earnings released on 29 Oct 2024
EPS came in at -$0.62 surpassing the estimated -$0.63 by +0.57%, while revenue for the quarter reached $30.53M , beating expectations by +56.90%.
Earnings released on 25 Jul 2024
EPS came in at -$0.67 falling short of the estimated -$0.41 by -65.91%, while revenue for the quarter reached $18.24M , missing expectations by -74.43%.
Earnings released on 21 May 2024
EPS came in at $0.14 falling short of the estimated $0.19 by -24.95%, while revenue for the quarter reached $11.11M , missing expectations by -0.38%.
Earnings released on 20 Mar 2024
EPS came in at -$0.76 surpassing the estimated -$0.91 by +15.86%, while revenue for the quarter reached $25.14M , missing expectations by -9.87%.
Earnings released on 30 Sept 2023
EPS came in at $1.37 surpassing the estimated -$1.06 by +229.50%, while revenue for the quarter reached $87.13M , beating expectations by +216.58%.
Earnings released on 30 Jun 2023
EPS came in at -$1.21 falling short of the estimated -$1.07 by -13.23%, while revenue for the quarter reached $33.37M , missing expectations by -9.70%.
Earnings released on 31 Mar 2023
EPS came in at -$1.30 falling short of the estimated -$1.17 by -10.90%, while revenue for the quarter reached $22.94M , missing expectations by -38.07%.
Earnings released on 7 Feb 2023
EPS came in at -$1.09 surpassing the estimated -$1.34 by +18.66%, while revenue for the quarter reached $58.50M , beating expectations by +64.51%.
Earnings released on 25 Oct 2022
EPS came in at -$1.22 matching the estimated -$1.22, while revenue for the quarter reached $21.08M , missing expectations by -12.27%.
Earnings released on 26 Jul 2022
EPS came in at -$1.24 matching the estimated -$1.24, while revenue for the quarter reached $17.83M , beating expectations by +15.12%.
Earnings released on 26 Apr 2022
EPS came in at -$1.12 surpassing the estimated -$1.14 by +1.75%, while revenue for the quarter reached $5.60M , missing expectations by -40.08%.
Earnings released on 8 Feb 2022
EPS came in at -$1.32 falling short of the estimated -$1.30 by -1.54%, while revenue for the quarter reached $5.44M , missing expectations by -32.28%.
Earnings released on 25 Oct 2021
EPS came in at -$0.83 surpassing the estimated -$1.06 by +21.70%, while revenue for the quarter reached $17.76M .
Earnings released on 27 Jul 2021
EPS came in at -$0.83 surpassing the estimated -$0.91 by +8.79%, while revenue for the quarter reached $7.54M .
Earnings released on 22 Apr 2021
EPS came in at -$0.63 surpassing the estimated -$0.85 by +25.88%, while revenue for the quarter reached $7.29M .
Earnings released on 4 Feb 2021
EPS came in at -$0.85 surpassing the estimated -$0.90 by +5.56%, while revenue for the quarter reached $6.59M .
Earnings released on 27 Oct 2020
EPS came in at -$0.83 surpassing the estimated -$0.85 by +2.35%, while revenue for the quarter reached $8.45M .
Stock split effective on 14 Oct 2020
Shares were split 1013 : 1000 , changing the number of shares outstanding and the price per share accordingly.
IDRSF Stock Performance
Access detailed IDRSF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.